USTOHAL, Libor, Michaela MAYEROVÁ, Veronika HUBLOVÁ, Hana PŘIKRYLOVÁ KUČEROVÁ, Eva ČEŠKOVÁ and Tomáš KAŠPÁREK. Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. Journal of Psychopharmacology. London, UK: SAGE Publications, 2017, vol. 31, No 4, p. 500-504. ISSN 0269-8811. Available from: https://dx.doi.org/10.1177/0269881116662650.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study
Authors USTOHAL, Libor (203 Czech Republic, guarantor, belonging to the institution), Michaela MAYEROVÁ (203 Czech Republic, belonging to the institution), Veronika HUBLOVÁ (203 Czech Republic, belonging to the institution), Hana PŘIKRYLOVÁ KUČEROVÁ (203 Czech Republic, belonging to the institution), Eva ČEŠKOVÁ (203 Czech Republic, belonging to the institution) and Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution).
Edition Journal of Psychopharmacology, London, UK, SAGE Publications, 2017, 0269-8811.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30100 3.1 Basic medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.738
RIV identification code RIV/00216224:14740/17:00096842
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1177/0269881116662650
UT WoS 000400179400010
Keywords in English Schizophrenia; cortical inhibition; cortical silent period; risperidone; transcranial magnetic stimulation
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 15/5/2018 09:03.
Abstract
Objectives: Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP). It is thought that CSP measures gamma-aminobutyric acid receptors B (GABA(B)) mediated inhibitory activity. But the mutual roles of schizophrenia as a disease and the drugs used for the treatment of psychosis on GABA mediated neurotransmission are not clear. Methods: We recruited 13 drug-naive patients with first-episode schizophrenia. We used transcranial magnetic stimulation to assess CSP prior to initiating risperidone monotherapy and again four weeks later. At the same time, we rated the severity of psychopathology using the Positive and Negative Syndrome Scale (PANSS). Results: We obtained data from 12 patients who showed a significant increase in CSP, from 134.2041.81 ms to 162.95 +/- 61.98 ms (p=0.041; Cohen's d=0.544). After the treatment, the PANSS total score was significantly lower, as were the individual subscores (p<0.05). However, no correlation was found between CSP and PANSS. Conclusion: Our study in patients with first-episode schizophrenia demonstrated an association between risperidone monotherapy and an increase in GABA(B) mediated inhibitory neurotransmission.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 23/5/2024 12:18